CytoDyn appoints Jacob Lalezari as CEO, Michael Cohen as interim CFO

CytoDyn announced that Dr. Jacob Lalezari, formerly interim CEO, was appointed to the CEO role, effective January 26, 2024. Dr. Lalezari’s appointment as CEO was made following a robust and competitive search process, carried out by the Company’s Board of Directors over the past seven months with support from international search advisers. In addition, the Company announced that Mitchell Cohen has been appointed to the role of interim CFO, effective February 1, 2024, following the resignation of Antonio Migliarese, effective January 31, 2024. Mr. Cohen will be working with Mr. Migliarese to facilitate a smooth transition over the next several weeks.